Praecis plans for Plenaxis

Following meetings with the FDA, PRCS said it will begin next quarter a trial to evaluate Plenaxis abarelix treatment followed by standard hormone therapy in patients with hormone-responsive advanced prostate cancer. PRCS said it expects to submit data from the new trial to the FDA by the end of 2002. ...